A Phase II study of Tranzyme Pharma’s TZP-102 capsules in diabetic patients with gastroparesis has demonstrated clinically significant improvements in critical symptoms.
The study, conducted on 92 patients with diabetic gastroparesis, found that more than 50% of those on TZP-102 had normalised gastric emptying.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
At the end of the once-daily, 28-day treatment period, patients on all three doses of TZP-102 showed positive results in symptom scores for nausea, early satiety, excessive fullness and postprandial fullness.
Diabetic gastroparesis is a serious disorder characterised by the inability of the stomach to empty food efficiently.
TZP-102 is an oral ghrelin agonist with potent prokinetic properties that has been developed to treat chronic gastrointestinal dysmotility disorders.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
